



ABN 53 075 582 740

ASX ANNOUNCEMENT

18 June 2021

CHANGE OF TELEPHONE NUMBER

Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (**Bionomics** or **Company**), a global, clinical stage biopharmaceutical company, announces in accordance with ASX Listing Rule 3.14, that, effective 21 June 2021, the Company's telephone number will change to:

Phone: +61 8 8150 7400

All other contact details remain as previously advised.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin
Company Secretary
+61 8 8354 6100
CoSec@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO, OTCQB: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.

www.bionomics.com.au